A5094195685- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Oral and Maxillofacial Pathology
- Lung Cancer Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Bone Tumor Diagnosis and Treatments
- Head and Neck Surgical Oncology
Homi Bhabha National Institute
2024-2025
Tata Memorial Hospital
2024-2025
Abstract Advanced/metastatic ALK-mutated lung cancer has excellent long-term survival due availability of multiple targeted drugs. Alectinib is one the preferred first-line therapies based on Alex trial data. We present a real-world outcome with alectinib in setting low- and middle-income country (LMIC) like India. conducted retrospective audit ALK positive patients who received at Medical Oncology Department, Tata Memorial Hospital, Mumbai, Maharashtra, included were started between January...
Background: This was the first Phase III randomized study comparing an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to standard-of-care chemotherapy (pemetrexed + carboplatin followed by pemetrexed maintenance) in advanced EGFR- mutated lung cancer. The initial interim analysis showed superiority of gefitinib over terms progression-free survival (PFS), objective response rate (ORR), and safety. Objectives: We aimed evaluate long-term outcomes. Our...
Osimertinib is approved in the first line patients with mutations sensitive gene epidermal growth factor receptor (EGFR) mutation. There lack of real-world evidence to illustrate effectiveness and safety osimertinib that can reflect current medical practice especially resource-constrained setting. A total 129 histology-proven metastatic non-small cell lung cancer EGFR mutation registered at Tata Memorial Hospital between from March 2018 May 2023 were analyzed. The parameters studied included...